Provider: View Press Release
Type: Link
Title: FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV | GSK
Description: Final FDA decision anticipated by 23 January 2022; if approved, cabotegravir would be the first long-acting therapy for HIV PrEP
Provider: View Press Release
Type: Link
Title: ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals | GSK
Description: S-365598 aims to build on the success of dolutegravir & cabotegravir with potential to anchor the next-gen pipeline of HIV therapies
Provider: View Press Release
Type: Link
Title: Changing attitudes to vaccination after the COVID-19 pandemic could increase adult vaccination rates, improving health outcomes over the longer term | GSK
Description: Survey shows that people 50 years of age and older value good health and improved quality of life
Provider: View Press Release
Type: Link
Title: ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021 | GSK
Description: ViiV Healthcare announce the presentation of 13 abstracts from its portfolio of pipeline prevention options.
Provider: View Press Release
Type: Link
Title: GSK announces major renewable energy investment and low carbon inhaler programme alongside Life Sciences sector Race to Zero ‘breakthrough’ at NYC Climate Week | GSK
Description: Company announces £50m investment in renewable energy and carbon reduction at major UK and US manufacturing sites
Provider: View Press Release
Type: Link
Title: GSK receives CHMP positive opinions recommending approval of Nucala (mepolizumab) in three additional eosinophil-driven diseases | GSK
Description: Eosinophil-driven diseases are inflammatory conditions associated with elevated levels of eosinophils, a type of white blood cell.